Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis
BACKGROUND: For bacterial infections, the susceptibility to antibiotics in vitro has been associated with clinical outcomes in vivo, although the importance of minimum inhibitory concentration (MIC) has been debated. In this study, we analyzed the association of MIC on clinical outcomes in bacterial corneal ulcers, while controlling for organism and severity of disease at presentation.
METHODS: Data were collected as part of a National Eye Institute-funded, randomized, controlled trial (the Steroids for Corneal Ulcers Trial [SCUT]). All cases enrolled in SCUT had a culture-positive bacterial corneal ulcer and received moxifloxacin. The MIC to moxifloxacin was measured by E test. Outcomes included best spectacle-corrected visual acuity, infiltrate/scar size, time to re-epithelialization, and corneal perforation.
RESULTS: Five hundred patients with corneal ulcers were enrolled in the trial, and 480 were included in this analysis. The most commonly isolated organisms were Streptococcus pneumoniae and Pseudomonas aeruginosa. A 2-fold increase in MIC was associated with an approximately 0.02 logMAR decrease in visual acuity at 3 weeks, approximately 1 letter of vision loss on a Snellen chart (0.019 logMAR; 95% confidence interval [CI], .0040-.033; P = .01). A 2-fold increase in MIC was associated with an approximately 0.04-mm larger infiltrate/scar size at 3 weeks (0.036 mm; 95% CI, .010-.061; P = .006). After controlling for organism, a higher MIC was associated with slower time to re-epithelialization (hazards ratio, 0.92; 95% CI, .86-.97; P = .005).
CONCLUSIONS: In bacterial keratitis, a higher MIC to the treating antibiotic is significantly associated with worse clinical outcomes, with approximately 1 line of vision loss per 32-fold increase in MIC.
CLINICAL TRIALS REGISTRATION: NCT00324168.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 54(2012), 10 vom: 24. Mai, Seite 1381-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lalitha, Prajna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 08.07.2013 Date Revised 21.10.2021 published: Print-Electronic ClinicalTrials.gov: NCT00324168 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/cis189 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM216488680 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM216488680 | ||
| 003 | DE-627 | ||
| 005 | 20231224031854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/cis189 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0721.xml |
| 035 | |a (DE-627)NLM216488680 | ||
| 035 | |a (NLM)22447793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lalitha, Prajna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2013 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00324168 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: For bacterial infections, the susceptibility to antibiotics in vitro has been associated with clinical outcomes in vivo, although the importance of minimum inhibitory concentration (MIC) has been debated. In this study, we analyzed the association of MIC on clinical outcomes in bacterial corneal ulcers, while controlling for organism and severity of disease at presentation | ||
| 520 | |a METHODS: Data were collected as part of a National Eye Institute-funded, randomized, controlled trial (the Steroids for Corneal Ulcers Trial [SCUT]). All cases enrolled in SCUT had a culture-positive bacterial corneal ulcer and received moxifloxacin. The MIC to moxifloxacin was measured by E test. Outcomes included best spectacle-corrected visual acuity, infiltrate/scar size, time to re-epithelialization, and corneal perforation | ||
| 520 | |a RESULTS: Five hundred patients with corneal ulcers were enrolled in the trial, and 480 were included in this analysis. The most commonly isolated organisms were Streptococcus pneumoniae and Pseudomonas aeruginosa. A 2-fold increase in MIC was associated with an approximately 0.02 logMAR decrease in visual acuity at 3 weeks, approximately 1 letter of vision loss on a Snellen chart (0.019 logMAR; 95% confidence interval [CI], .0040-.033; P = .01). A 2-fold increase in MIC was associated with an approximately 0.04-mm larger infiltrate/scar size at 3 weeks (0.036 mm; 95% CI, .010-.061; P = .006). After controlling for organism, a higher MIC was associated with slower time to re-epithelialization (hazards ratio, 0.92; 95% CI, .86-.97; P = .005) | ||
| 520 | |a CONCLUSIONS: In bacterial keratitis, a higher MIC to the treating antibiotic is significantly associated with worse clinical outcomes, with approximately 1 line of vision loss per 32-fold increase in MIC | ||
| 520 | |a CLINICAL TRIALS REGISTRATION: NCT00324168 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Aza Compounds |2 NLM | |
| 650 | 7 | |a Fluoroquinolones |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 650 | 7 | |a Moxifloxacin |2 NLM | |
| 650 | 7 | |a U188XYD42P |2 NLM | |
| 700 | 1 | |a Srinivasan, Muthiah |e verfasserin |4 aut | |
| 700 | 1 | |a Manikandan, P |e verfasserin |4 aut | |
| 700 | 1 | |a Bharathi, M Jayahar |e verfasserin |4 aut | |
| 700 | 1 | |a Rajaraman, Revathi |e verfasserin |4 aut | |
| 700 | 1 | |a Ravindran, Meenakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Cevallos, Vicky |e verfasserin |4 aut | |
| 700 | 1 | |a Oldenburg, Catherine E |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Kathryn J |e verfasserin |4 aut | |
| 700 | 1 | |a Toutain-Kidd, Christine M |e verfasserin |4 aut | |
| 700 | 1 | |a Glidden, David V |e verfasserin |4 aut | |
| 700 | 1 | |a Zegans, Michael E |e verfasserin |4 aut | |
| 700 | 1 | |a McLeod, Stephen D |e verfasserin |4 aut | |
| 700 | 1 | |a Acharya, Nisha R |e verfasserin |4 aut | |
| 700 | 1 | |a Lietman, Thomas M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 54(2012), 10 vom: 24. Mai, Seite 1381-7 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2012 |g number:10 |g day:24 |g month:05 |g pages:1381-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/cis189 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2012 |e 10 |b 24 |c 05 |h 1381-7 | ||